Andrew Ko, MD, FASCO, University of California, San Francisco, CA, comments on the role of precision medicine in pancreatic cancer. Whilst next-generation sequencing (NGS) is becoming more integral in the profiling of patients, a relatively small number of patients have targetable mutations, limiting the use of precision medicine. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть